Corton Capital’s BridgeBio Pharma BBIO Stock Holding History

Corton Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-11,029	Closed	-$279K	–	495
2024 Q2	$279K	Buy	+11,029	New	+$302K	0.15%	218
2023 Q4	–	Sell	-8,711	Closed	-$230K	–	576
2023 Q3	$230K	Sell	8,711 -1,841	-17%	-$52.2K	0.12%	274
2023 Q2	$181K	Buy	+10,552	New	+$159K	0.09%	349
2022 Q4	–	Sell	-30,496	Closed	-$303K	–	307
2022 Q3	$303K	Sell	30,496 -8,633	-22%	-$89.7K	0.37%	103
2022 Q2	$355K	Sell	39,129 -12,202	-24%	-$102K	0.34%	108
2022 Q1	$521K	Buy	+51,331	New	+$527K	0.23%	106

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corton Capital's BBIO Position: Q3 2024 in Review

Corton Capital sold out of BridgeBio Pharma (BBIO) in Q3 2024, closing a stake of 11,029 shares — an estimated $279K sold.

Corton Capital first reported a position in BBIO in Q1 2022 and held it in 6 quarters. The position peaked at $521K in Q1 2022. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

Corton Capital reported no remaining BridgeBio Pharma position as of Q3 2024 after selling out during the quarter.
Corton Capital sold 11,029 BridgeBio Pharma shares in Q3 2024, an estimated $279K.
Corton Capital first reported a position in BridgeBio Pharma in Q1 2022 and held it in 6 quarters.
Corton Capital's BridgeBio Pharma position peaked at $521K in Q1 2022.
253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on Corton Capital's 13F filing for Q3 2024, filed 14 Nov 2024.